Oncology Search
Oncology Oncology
Most Read Articles
ARROW: Pralsetinib achieves potent and durable responses in RETmut medullary thyroid cancer
Natalia Reoutova, 2 days ago

Results of the registrational phase I/II ARROW trial of pralsetinib, presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020, reveal overall response rates (ORRs) of ≥60 percent in pretreated and treatment-naïve RET-mutated (RETmut) medullary thyroid cancer (MTC) patients.

Podcast: Dr Susana Benerjee says more women should be getting PARP inhibitors in the first-line setting

11 Oct 2019
Podcast: Dr Susana Benerjee says more women should be getting PARP inhibitors in the first-line setting
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
ARROW: Pralsetinib achieves potent and durable responses in RETmut medullary thyroid cancer
Natalia Reoutova, 2 days ago

Results of the registrational phase I/II ARROW trial of pralsetinib, presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020, reveal overall response rates (ORRs) of ≥60 percent in pretreated and treatment-naïve RET-mutated (RETmut) medullary thyroid cancer (MTC) patients.